Canine Diabetes Insipidus Study Guide

Overview and Clinical Importance

Diabetes insipidus (DI) is a rare endocrine disorder characterized by the production of large volumes of dilute urine and compensatory polydipsia. Unlike diabetes mellitus, which involves abnormal glucose metabolism, diabetes insipidus results from dysfunction in the antidiuretic hormone (ADH) pathway. The term "insipidus" derives from Latin meaning "tasteless," referring to the dilute, tasteless urine produced by affected patients, in contrast to the sweet urine of diabetes mellitus.

Understanding diabetes insipidus is essential for NAVLE success because it requires differentiation from numerous other causes of polyuria and polydipsia, a common clinical presentation in small animal practice. The condition demonstrates fundamental concepts in endocrine physiology, renal function, and diagnostic reasoning.

Pathophysiology of Diabetes Insipidus

Normal ADH Physiology

Antidiuretic hormone (ADH), also known as arginine vasopressin (AVP), is a nonapeptide hormone synthesized in the supraoptic and paraventricular nuclei of the hypothalamus. The hormone is transported along axons through the infundibular stalk and stored in the posterior pituitary gland (neurohypophysis) until release.

Diagram showing the hypothalamic-pituitary axis with ADH synthesis in the supraoptic and paraventricular nuclei and release from the posterior pituitary (Figure 1)

ADH release is triggered by:

• Increased plasma osmolality (detected by hypothalamic osmoreceptors)
• Decreased blood volume or pressure (detected by baroreceptors)
• Angiotensin II stimulation

Mechanism of Action: ADH binds to V2 receptors on the basolateral membrane of principal cells in the renal collecting duct. This activates adenylate cyclase, increasing intracellular cAMP, which activates protein kinase A. The cascade leads to insertion of aquaporin-2 (AQP2) water channels into the apical membrane, dramatically increasing water permeability and allowing water reabsorption from the tubular lumen into the hypertonic medullary interstitium.

Classification of Diabetes Insipidus

Central Diabetes Insipidus (CDI)

Central diabetes insipidus results from partial or complete deficiency of ADH synthesis or secretion. At least 80-90% of ADH-producing neurons must be destroyed before clinical signs become apparent.

Etiologies of CDI:

• Idiopathic: Most common cause; may represent undetected autoimmune destruction
• Neoplasia: Pituitary tumors (approximately 40% of CDI cases), craniopharyngioma, pituitary chromophobe adenoma/adenocarcinoma, metastatic tumors
• Trauma: Head injury, skull fractures (may cause transient or permanent CDI)
• Congenital malformations: Pituitary cysts, hypothalamic-pituitary malformations
• Inflammatory/Infectious: Lymphocytic hypophysitis, granulomatous disease, encephalitis
• Iatrogenic: Post-hypophysectomy (common complication)

Nephrogenic Diabetes Insipidus (NDI)

Nephrogenic diabetes insipidus occurs when the kidneys fail to respond appropriately to ADH despite normal or elevated plasma ADH concentrations. NDI can be primary (congenital) or secondary (acquired).

Primary (Congenital) NDI:

• Rare congenital defect in V2 receptor or aquaporin-2 channels
• Clinical signs typically appear by 8-12 weeks of age
• Breed predispositions: German Shepherds, Miniature Poodles, Siberian Huskies

Secondary (Acquired) NDI - More Common:

• Chronic kidney disease (CKD)
• Hypercalcemia
• Hypokalemia
• Hyperadrenocorticism (cortisol antagonizes ADH action)
• Pyometra/endotoxemia
• Pyelonephritis
• Leptospirosis
• Drugs (glucocorticoids, certain antibiotics)
• Hepatic disease

Comparison: CDI vs NDI

Clinical Presentation

Clinical Signs

The hallmark clinical signs of diabetes insipidus are profound polyuria (PU) and polydipsia (PD). These signs can be dramatic and often bring the patient to clinical attention.

Key Clinical Features:

• Polyuria: Urine production greater than 50 mL/kg/day (normal: 20-45 mL/kg/day)
• Polydipsia: Water consumption greater than 100 mL/kg/day (normal: 20-70 mL/kg/day)
• Extreme water consumption: May exceed 200-800 mL/kg/day in severe cases
• Urinary incontinence (due to bladder distension from urine volume)
• Nocturia (urination at night)
• House soiling (previously house-trained dogs)
• Dehydration (if water access is restricted)
• Weight loss (occasionally, due to preoccupation with drinking)

Exam Focus: CRITICAL - Dogs with complete DI can become severely dehydrated within 4-6 hours if water is withheld. This is clinically important for hospitalized patients and before anesthesia. Always ensure free water access is available.

Physical Examination Findings

Physical examination is often unremarkable in uncomplicated diabetes insipidus. Key findings may include:

• Normal body condition (unless severe dehydration)
• Distended urinary bladder on palpation
• Dehydration signs if water restricted: tacky mucous membranes, prolonged skin tent, sunken eyes
• Neurological signs if pituitary mass effect present: blindness, circling, seizures, behavioral changes

Diagnostic Approach

Initial Diagnostic Workup

The diagnosis of diabetes insipidus requires a systematic approach to first exclude more common causes of PU/PD before pursuing specific testing.

Minimum Database

Urine Specific Gravity (USG) Interpretation

Desmopressin (DDAVP) Trial - Preferred Diagnostic Test

The desmopressin trial is now the preferred diagnostic approach as it is safer than water deprivation testing and provides both diagnostic and therapeutic information.

Protocol:

• Establish baseline: Owner measures 24-hour water intake for 2-3 days and collects daily urine samples
• Administer desmopressin: 0.1-0.2 mg PO every 8-12 hours OR 1-4 drops (conjunctival) every 12 hours for 5-7 days
• Continue monitoring water intake and urine collection during treatment
• Evaluate response after 5-7 days (allows time to overcome medullary washout)

Interpretation:

• CDI: Greater than 50% decrease in water intake; USG increases significantly (greater than 1.015-1.025)
• NDI: Minimal to no change in water intake or USG
• Partial CDI: Moderate improvement (partial response)

Modified Water Deprivation Test

Note: This test has largely fallen out of favor due to significant risks including severe dehydration, hypernatremia, neurological signs, and potential death in dogs with complete DI. The desmopressin trial is preferred. However, understanding this test is important for board examinations.

Protocol Overview:

• Gradual water restriction over several days prior to test
• Complete water withholding with close monitoring
• Monitor body weight, hydration status, USG every 1-2 hours
• Stop test if: greater than 5% body weight loss, severe dehydration, USG greater than 1.030
• Administer exogenous ADH (desmopressin) and monitor response

Advanced Imaging

If CDI is diagnosed, MRI or CT scan of the brain is recommended to evaluate for pituitary masses. Up to 40% of dogs with CDI have an underlying pituitary tumor.

Figure 2: Transverse post-contrast T1-W MR image of the brain from a dog with a DPM.

Reference: Menchetti M, De Risio L, Galli G, Bruto Cherubini G, Corlazzoli D, Baroni M, Gandini G. Neurological abnormalities in 97 dogs with detectable pituitary masses. Vet Q. 2019 Dec;39(1):57-64. doi: 10.1080/01652176.2019.1622819. PMID: 31112462; PMCID: PMC6831018.

Treatment Options

Treatment of Central Diabetes Insipidus

Desmopressin (DDAVP) is the treatment of choice for CDI. It is a synthetic vasopressin analog with potent V2 receptor activity (antidiuretic effect) and minimal V1 activity (vasopressor effect).

Desmopressin Dosing Protocols

Monitoring and Dose Adjustment

• Maximal effect occurs 2-8 hours after administration
• Duration of action: 8-24 hours (variable)
• Titrate dose to effect based on water intake and urine output
• Monitor for overhydration: vomiting, diarrhea, neurological signs (hyponatremia)
• DO NOT restrict water access

Treatment of Nephrogenic Diabetes Insipidus

Treatment of NDI is more challenging as the kidneys do not respond to ADH. The primary approach is to treat any underlying cause for acquired NDI.

Prognosis

Central Diabetes Insipidus: Prognosis is generally good with lifelong desmopressin therapy, provided there is no underlying pituitary tumor. Dogs can live normal lifespans with appropriate treatment and free water access. If a pituitary tumor is present, prognosis depends on tumor type and size.

Trauma-induced CDI: May be transient (resolving in days to weeks) or permanent. Prophylactic desmopressin post-hypophysectomy can minimize CDI development.

Nephrogenic Diabetes Insipidus: Prognosis varies. Acquired NDI may resolve with treatment of the underlying condition. Congenital NDI is irreversible but can be managed. Quality of life can be significantly impacted by the need for constant water access and frequent urination.

Differential Diagnosis of Polyuria/Polydipsia

Always consider and rule out more common causes of PU/PD before pursuing specific DI diagnostics: